Ventricular Arrhythmia Risk Due to Hydroxychloroquine-Azithromycin Treatment For COVID-19

The article listed on is authored by Timothy F. Simpson, MD, PharmD, Oregon Health & Science University; Richard J. Kovacs, MD, MACC, Indiana University School of Medicine; and Eric C. Stecker, MD, MPH, FACC, Oregon Health & Science University.

Highlights From Article

  • “Safety considerations for inpatient and outpatient use of hydroxychloroquine and chloroquine in clinical practice are outlined below.”
  • “Hydroxychloroquine or chloroquine therapy should occur in the context of a clinical trial or registry, until sufficient evidence is available for use in clinical practice.”
  • “Hydroxychloroquine or chloroquine use outside of a clinical trial should occur at the direction of an infectious disease or COVID-19 expert, with cardiology input regarding QT monitoring.”
  • Additional sources of expert guidance with detailed and general arrhythmia monitoring considerations are also available.”
  • “The intensity of QT and arrhythmia monitoring should be considered in the context of potential drug benefit, drug safety, resource availability and quarantine considerations.”
  • “IRB-approved protocols should guide use of hydroxychloroquine or chloroquine for pandemic research; suggestions for researchers are outlined here.”

The above is a direct excerpt taken from the article “Ventricular Arrhythmia Risk Due to Hydroxychloroquine-Azithromycin Treatment For COVID-19” on the American College of Cardiology.